These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28623073)

  • 21. Platinum sensitivity in metastatic prostate cancer: does histology matter?
    Humeniuk MS; Gupta RT; Healy P; McNamara M; Ramalingam S; Harrison M; George D; Zhang T; Wu Y; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):92-99. PubMed ID: 29230006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
    Iwasawa T; Kosaka T; Morita S; Mikami S; Nakamura K; Hongo H; Nishihara H; Oya M
    BMC Med Genomics; 2022 Jun; 15(1):138. PubMed ID: 35725469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequencing Treatment for Castration-Resistant Prostate Cancer.
    Handy CE; Antonarakis ES
    Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8.
    Liang J; Beckta JM; Bindra RS
    Eur Urol; 2019 Oct; 76(4):e109-e110. PubMed ID: 31080125
    [No Abstract]   [Full Text] [Related]  

  • 29. Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.
    Romero-Laorden N; Piñeiro-Yañez E; Gutierrez-Pecharroman A; Pacheco MI; Calvo E; Al-Shahrour F; Castro E; Olmos D
    Ann Oncol; 2017 May; 28(5):1158-1159. PubMed ID: 28453706
    [No Abstract]   [Full Text] [Related]  

  • 30. [Efficacy of carboplatin chemotherapy in a metastatic, castration-resistant BRCA2 mutation positive prostate cancer patient].
    Nagy ND; Fazekas T; Baghy K; Papp G; Csizmarik A; Szűcs M; Nyirády P; Szarvas T
    Orv Hetil; 2021 Jun; 162(25):1004-1008. PubMed ID: 34148027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
    De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
    Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology.
    Grypari IM; Tzelepi V; Gyftopoulos K
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
    Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
    Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA2 and pancreatic cancer.
    Naderi A; Couch FJ
    Int J Gastrointest Cancer; 2002; 31(1-3):99-106. PubMed ID: 12622420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The resounding effect of DNA repair deficiency in prostate cancer.
    Cheng HH
    Urol Oncol; 2018 Aug; 36(8):385-388. PubMed ID: 29555412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    Castro E; Mateo J; Olmos D; de Bono JS
    Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer.
    Aggarwal R
    Eur Urol; 2018 May; 73(5):694-695. PubMed ID: 29458985
    [No Abstract]   [Full Text] [Related]  

  • 39. Mutations in BRCA2 and taxane resistance in prostate cancer.
    Nientiedt C; Heller M; Endris V; Volckmar AL; Zschäbitz S; Tapia-Laliena MA; Duensing A; Jäger D; Schirmacher P; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
    Sci Rep; 2017 Jul; 7(1):4574. PubMed ID: 28676659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mixed ovarian germ cell tumor in a BRCA2 mutation carrier.
    Hamel N; Wong N; Alpert L; Galvez M; Foulkes WD
    Int J Gynecol Pathol; 2007 Apr; 26(2):160-4. PubMed ID: 17413983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.